Treatment for breast cancer that has spread to the liver using a new ablation technique
Official title: A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
Run by Ruijin Hospital · NCT06567353 · Data updated 2026-11-12
This study is testing a new treatment method for breast cancer that has spread to the liver to see if it works better than the standard approach.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | Women only |
| Enrollment | 10 (estimated) |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | December 9, 2024 |
| Main results expected | July 2027 |
| Study ends | December 2027 |
| Registry record updated | March 14, 2025 |
| Trial ID | NCT06567353 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women aged 18-75 with pathologically confirmed breast cancer liver metastases who are unable to tolerate or refuse surgical resection.
✕Probably not a fit
Patients with severe liver dysfunction, widespread metastasis, or other significant health issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical study evaluates the safety and effectiveness of a multi-mode integrated ablation system for treating breast cancer liver metastases. It is a single-center, parallel-controlled study involving 10 participants, with half receiving the experimental treatment and the other half undergoing conventional radiofrequency ablation. The study will assess the impact of the new technique on systemic anti-tumor immunity, comparing outcomes between the two groups over a defined treatment and follow-up period.
Why it matters
Potential benefit: If successful, this treatment could provide a more effective option for patients with breast cancer liver metastases who cannot undergo surgery.
How similar studies have gone: While similar approaches have been explored, this specific multi-mode thermophysical immunotherapy technique is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18-75 years, female gender; 2. Pathologically confirmed breast cancer liver metastases, in patients who are unable to tolerate or refuse surgical resection; 3. The number of lesions ≤ 3, with any single lesion diameter ≤ 4cm; 4. At least an interval of 1 month since the last local treatment; 5. Child-Pugh class A or B; 6. ECOG PS score ≤2, with an expected survival of \>3 months. Exclusion Criteria: 1. Liver function Child-Pugh class C; 2. Systemic widespread metastasis, with an expected survival of \< 3 months; 3. History of esophageal (gastric fundus) variceal bleeding within the past month; 4. Dysfunction or failure of vital organs; 5. Presence of an active infection; 6. Irreparable coagulation abnormality; 7. Refractory massive ascites, pleural effusion or cachexia; 8. Pregnancy, altered consciousness or patients unable to cooperate with treatment; 9. Previously participated in other clinical studies and still within the follow-up period; 10. Any other factors deemed inappropriate for inclusion or that may affect the patient's participation in the study, as determined by the investigator.
Where it's running
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improved Facial Skin Quality After VYC-12L for Breast Cancer Survivors
This study tests whether intradermal injections of VYC-12L can improve facial skin quality and quality of life in adults who have completed breast cancer treatment.
-
Breast cancer subtypes and outcomes in Colombian women
This study looks back at medical records of women with breast cancer to see how different molecular subtypes relate to survival and recurrence in a single Colombian hospital.
-
Multimodal Survival Predictor for Colorectal Liver Metastases After Surgery
Researchers are testing a tool that combines MRI-derived tumor features with clinical data to predict survival after surgery for colorectal liver metastases.
-
Multimodal psychosomatic symptom care for breast cancer: personalized acupuncture care guided by shared decision-making
This study tests whether personalized acupuncture options (manual acupuncture, ear acupuncture, or both) can help women with breast cancer who have anxiety, sleep problems, or fatigue, compared to routine nursing care.
-
Slow Jogging for Breast Cancer Survivors
This study tests whether a 12-week slow jogging program helps sleep quality in women who have completed breast cancer treatment.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.